Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study - Poll - MDSpire

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • By

  • Matthias Augustin

  • Paul-Gunther Sator

  • Ralph von Kiedrowski

  • Dimitris Rigopoulos

  • Marco Romanelli

  • Pierre-Dominique Ghislain

  • Tiago Torres

  • Dimitrios Ioannides

  • Cynthia Vizcaya

  • Andreas Clemens

  • Weibin Bao

  • Christelle C. Pieterse

  • Barbara Schulz

  • Piotr Jagiello

  • Curdin Conrad

  • April 2, 2026

  • 0 min

Share

Original Source(s)

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • by Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, Dimitris Rigopoulos, Marco Romanelli, Pierre-Dominique Ghislain, Tiago Torres, Dimitrios Ioannides, Cynthia Vizcaya, Andreas Clemens, Weibin Bao, Christelle C. Pieterse, Barbara Schulz, Piotr Jagiello, Curdin Conrad

  • April 2, 2026

Related Content

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada

UVB and Psoriasis: More Than Immunosuppression

UVB's benefits may run deeper than inflammation suppression—cholesterol metabolism could be a key link.